Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.52 |
| ▸ | METAP1 | P53582 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612959 | 0.82 | METAP2 (0.49) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL7612965 | 0.82 | METAP2 (0.49) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL8518963 | 0.76 | LMNA (0.61) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL2934798 | 0.76 | LMNA (0.61) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL7263715 | 0.76 | LMNA (0.61) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL6891376 | 0.75 | METAP2 (0.49) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL3356973 | 0.73 | METAP2 (0.61) | METAP2METAP1EPHX2LMNAGAA | |
| Trifluoroacetic Acid SCHEMBL3338958 | 0.71 | HDAC3 (0.60) | METAP2METAP1EPHX2LMNAGAA | |
| SCHEMBL6193303 | 0.71 | NPC1 (0.56) | LMNA | |
| SCHEMBL3627449 | 0.71 | NPC1 (0.56) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | METAP2 1100/4885METAP1 489/4885EPHX2 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.